Answers are grounded in this paper and cite their sources.
Demonstrates techno-economic optimization of monoclonal antibody production platforms, suggesting enhanced manufacturing efficiencies.
Design variables of upstream and downstream process units play a significant role in the performance of monoclonal antibody (mAb) production platforms. Plantwide optimization problems in the form of mixed integer nonlinear programming (MINLP) must consider decision variables, process constraints and a suitable objective function to achieve meaningful solutions. Moreover, deterministic MINLP solvers are required to avoid simulation-based pitfalls. In this study, a deterministic branch-and-bound method employs the BONMIN solver to obtain credible solutions to the non-convex MINLP problem established from a plantwide optimization flowsheet, which simultaneously considers an upstream mAb producing bioreactor and downstream separation design variables. The BONMIN solver has thus been employed here to solve a chromatography sequencing and column sizing problem, where the cost of goods sold metric is optimized, and a minimum annual mAb throughput is achieved. The plantwide MINLP problem that has been formulated integrates upstream bioreactor design, chromatography sequencing and column sizing, simultaneously addressing all for techno-economic optimization. The results obtained are analysed in order to pinpoint the integrated upstream–downstream technologies and operating strategies holding the strongest promise for industrial mAb manufacturing.
No takes yet. Share an insight, caveat, or question.
Jones et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: